CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CIDP drug challenger: can riliprubart beat IVIg?
Disease control Recruiting nowThis study compares a new medicine called riliprubart to the standard treatment, IVIg, for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 160 participants who are already stable on IVIg will be randomly …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New CIDP drug aims to keep patients Relapse-Free
Disease control Recruiting nowThis study tests an investigational drug called IMVT-1402 (Imeroprubart) in 162 adults with CIDP, a nerve disorder that causes weakness and numbness. The goal is to see if the drug can prevent relapses and improve daily function compared to a placebo. Participants must already be…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
New drug aims to control rare nerve disorder in major trial
Disease control Recruiting nowThis study tests a new medicine called DNTH103 (claseprubart) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system attacks nerves, causing weakness and disability. The trial will compare the drug to a placebo in 256 people …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
Engineered immune cells take aim at Hard-to-Treat nerve diseases
Disease control Recruiting nowThis early-phase study tests a new treatment called KITE-363 for people with severe autoimmune nerve diseases like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy that haven't responded to standard therapies. KITE-363 uses a patient's …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New CIDP drug shows promise in Head-to-Head trial against standard care
Disease control Recruiting nowThis study compares a new intravenous drug, empasiprubart, to standard intravenous immunoglobulin (IVIg) in 218 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. Participants first receive either empasiprubart or…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New CIDP drug trial offers hope for nerve damage relief
Disease control Recruiting nowThis study tests a new drug called empasiprubart for adults with CIDP, a condition that causes nerve damage and weakness. About 160 people will receive either the drug or a placebo for 6 months, then everyone gets the drug for 2 more years. The goal is to see if it improves disab…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New study aims to find best dose of immune therapy for nerve disorder
Disease control Recruiting nowThis study tests two different doses of a medicine called KIg10 (a type of immune globulin given through a vein) to see which works better as a long-term treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New hope for nerve disease patients: blood-filtering therapy tested in 140-person study
Disease control Recruiting nowThis study looks at whether a blood-filtering procedure called immunoadsorption (IA) can safely and effectively help people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. About 140 adults who are already on stand…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Sponsor: University of Ulm • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
Shocking muscles back to life: new exercise hope for ALS and SMA patients
Symptom relief Recruiting nowThis study tests a special exercise method using whole-body electrical muscle stimulation (WB-EMS) in adults with neuromuscular diseases like ALS, SMA, and muscular dystrophy. Because these conditions make normal exercise hard, WB-EMS directly triggers muscle contractions without…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: NA • Sponsor: University of Missouri-Columbia • Aim: Symptom relief
Last updated May 15, 2026 11:54 UTC
-
Body shape may change how drug works for nerve disease
Knowledge-focused Recruiting nowThis study looks at whether a person's body composition (like muscle and fat) changes how immunoglobulin G (IgG) is processed after IV or under-the-skin injections. Researchers will measure drug levels and half-life in 20 adults with CIDP, a nerve condition. The goal is to improv…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated May 14, 2026 12:01 UTC